REDWOOD CITY, Calif., Oct. 9, 2018 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced that its Oncotype DX Breast Recurrence Score ® test has been categorized as the only "preferred" ...

REDWOOD CITY, Calif., Aug. 21, 2019 /PRNewswire/ -- Genomic Health today announced that, based on results from the prospective TAILORx1 and PlanB2 studies, the 16th St. Gallen International Breast ...

The investigators reported the results of a prospective, randomized, phase 3 trial studying the best individual therapy for women who have node-negative, estrogen-receptor‒positive (ER-positive) ...

Oncotype Dx Recurrence Score (RS) is prognostic and predictive of chemotherapy benefit in women with node-negative and node-positive in hormone receptor–positive (HR+), human epidermal growth factor ...

Correlation of PITX2 gene expression and invasive potential of breast cancer cells. Background: The Oncotype Dx recurrence score (RS) has been widely adopted by oncologists to guide adjuvant ...

Exact Sciences, a leading provider of cancer screening and diagnostic tests, today announced that the UK’s National Institute for Health and Care Excellence (NICE) has recommended the expanded use of ...

Initial results were announced today from the Trial Assigning IndividuaLized Options for Treatment (Rx), or TAILORx, a multi-center prospectively conducted trial of more than 10,000 women with early ...

While several studies have demonstrated that the Oncotype DX Recurrence Score can help predict locoregional recurrence in patients with hormone receptor-positive breast cancer, it’s less clear whether ...

A cost-effectiveness analysis has found that Oncotype DX may not be economical to make clinical decisions on adjuvant radiation treatment in patients with DCIS. A part of precision medicine involves ...

Please provide your email address to receive an email when new articles are posted on . Similar proportions of older women with node-negative and node-positive early breast cancer had Oncotype Dx ...